Tesamorelin CAS:804475-66-9 Unii-mqg94m5eeo Th 9507

Tesamorelin (INN) (trade name Egrifta SV) is a synthetic form of growth hormone releasing hormone (GHRH) for the treatment of HIV-associated lipodystrophy and was originally approved in 2010. It is produced and developed by Theratechnologies, Inc. Canada. The drug is a synthetic peptide composed of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group

Mechanism of action
Tesamorelin is an N-terminus modified compound based on the 44 amino acid sequence of human GHRH. This modified synthetic form is more effective and stable than natural peptides. It is also more resistant to cleavage by dipeptide aminopeptidase than human GHRH. It stimulates endogenous GH synthesis and release and increases levels of insulin-like growth factor (IGF-1). The released GH then binds to receptors present on various body organs and regulates body composition. This regulation is mainly due to the combination of anabolic and lipolysis mechanisms. However, the main mechanism by which tesamoline has been found to reduce body fat mass is the reduction of triglyceride levels after lipolysis.